We are live on ! Find out more
ATXI

Avenue Therapeutics, Inc. Common Stock
ATXI

Delisted

ATXI was delisted on the 18th of March, 2025.

Back to rankings

2 hedge funds and large institutions have $228K invested in Avenue Therapeutics, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
2
Holders Change
+2
Holders Change %
–
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$216K
2
UBS Group
UBS Group
Switzerland
+$9K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
1
Goldman Sachs
New York
$219K +$216K +24 New
UBS Group
2
UBS Group
Switzerland
$9K +$9K +1 New

ATXI Hedge Fund Activity: Q2 2017 in Review

2 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q2 2017, worth a combined $228K.

Buyers outnumbered sellers: 2 funds opened new ATXI positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $216K.

  • 2 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q2 2017, up from 0 in Q1 2017.
  • Funds reported $228K of Avenue Therapeutics, Inc. Common Stock stock for Q2 2017.
  • 2 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q2 2017 and 0 closed out, a net change of +2 holders.
  • The largest Avenue Therapeutics, Inc. Common Stock buyer in Q2 2017 was Goldman Sachs, an estimated $216K added.

Based on aggregated 13F filings for Q2 2017.